Home/Pipeline/CEL-202

CEL-202

Solid Tumors

Phase I/IIActive

Key Facts

Indication

Solid Tumors

Phase

Phase I/II

Status

Active

Company

Celon Pharma

About Celon Pharma

Celon Pharma's mission is to develop and provide innovative therapies for diseases with significant unmet medical needs, primarily in oncology and CNS, while maintaining financial stability through its generic drug operations. Its key achievement is building a fully integrated, GMP/GLP-compliant biopharma platform in Poland, supporting a pipeline of 11 proprietary drug candidates. The company's strategy is defined by this self-funded, end-to-end model, which reduces external dependencies and aims to capture full value from its R&D successes. This approach has established Celon as a unique and strategically important player in the European biopharmaceutical landscape.

View full company profile

Therapeutic Areas

Oncology Central Nervous System (CNS)

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active
SY-5609	Syros Pharmaceuticals	Phase 1/2	Discontinued
Not Specified (TCR Therapy)	T-Cure Bioscience	Phase 1	Active
B7-H3 Program	Ocean Biomedical	Discovery	Active